CoChat

Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review

Open access

The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index; none of the 61 sources its claims cite is checked for support yet.

Abstract

Purpose: A systematic literature review was conducted to estimate the global prevalence of Kirsten rat sarcoma virus gene (KRAS) mutations, with an emphasis on the clinically significant KRAS G12C mutation, and to estimate the prognostic significance of these mutations in patients with colorectal cancer (CRC). Design: Relevant English-language publications in the Embase, MEDLINE, and the Cochrane Library databases (from 2009 to 2021) and congress presentations (from 2016 to 2021) were reviewed. Eligible studies were those that reported the prevalence and clinical outcomes of the KRAS G12C mutation in patients with CRC. Results: A total of 137 studies (interventional [n = 8], post hoc analyses of randomized clinical trials [n = 6], observational [n = 122], and longitudinal [n =1]) were reviewed. Sixty-eight studies reported the prevalence of KRAS mutations (KRASm) in 42 810 patients with CRC. The median global prevalence of KRASm was 38% (range, 13.3%-58.9%) and that of the KRAS G12C mutation (KRAS G12C) 3.1% (range, 0.7%-14%). Available evidence suggests that KRASm are possibly more common in tumors that develop on the right side of the colon. Limited evidence suggests a lower objective response rate and inferior disease-free/relapse-free survival in patients with KRAS G12C compared with patients with KRASwt or other KRASm. Conclusion: Our analysis reveals that KRAS G12C is prevalent in 3% of patients with CRC. Available evidence suggests a poor prognosis for patients with KRAS G12C. Right-sided tumors were more likely to harbor KRASm; however, their role in determining clinical outcomes needs to be investigated further.

Overview

CoChat Summary

TL;DR

This systematic literature review of 137 publications estimated a median global prevalence of KRAS G12C of 3.1% (range 0.7%-14%) in colorectal cancer, with KRAS mutations overall at 38% (range 13.3%-58.9%). Limited evidence suggested that KRAS G12C is associated with poorer prognosis, including shorter OS, PFS, and DFS, compared with KRAS wild-type or other KRAS mutations.

Key findings

  • In 68 studies reporting prevalence in 42,810 patients with CRC, median global KRASm prevalence was 38% (range 13.3%-58.9%) and median KRAS G12C prevalence was 3.1% (range 0.7%-14%); within KRASm, median KRAS G12C prevalence was 7.7% (range 1.9%-39.7%).
  • Regional median KRAS G12C prevalence was 3.8% in Europe (range 1.3%-7.8%), 4.0% in North America (range 0.8%-9.2%), 2.5% in Japan/Asia-Pacific (range 0.7%-14.0%), and 2.9% in the intercontinental region (range 1.0%-11.3%).
  • Among 17 publications reporting OS and/or PFS, 11 reported shorter OS/PFS for KRAS G12C than KRASwt or other KRASm; examples included median OS 28.9 vs 36.7 months vs other KRASm and 23 vs 27.1 months (P < .001). ORR was 17.0% for KRAS G12C vs 46.0% for KRAS G12D in one post hoc analysis; 3-year DFS was 61.0% vs 77% for KRASwt (HR 1.66, 95% CI 1.14-2.41; P = .008), and 3-year RFS was 33.3% vs 81.9% (HR 6.57, 95% CI 1.90-17.7; P < .001).
  • Five studies noted right-sided colon tumors were more likely to harbor KRASm; evidence on KRAS G12C and tumor sidedness was limited.

Methods

  • PRISMA-P/PICO systematic literature review; searched Embase, MEDLINE, Cochrane Library (January 2009-July 2021) and congress abstracts (2016-2021) in two phases.
  • Included RCTs, single-arm trials, and observational studies of CRC patients with KRAS G12C; excluded non-English publications, editorials, reviews, animal/in vitro studies, and case reports/case studies. Prevalence data were extracted only when total study population was ≥100 patients or prevalence was the primary aim; clinical outcome data were extracted from all relevant publications.
  • 137 publications were selected: 8 interventional (6 single-arm, 2 RCTs), 6 post hoc analyses, 122 observational, 1 longitudinal; 68 studies reported prevalence in 42,810 patients, and 31 publications reported clinical outcomes with KRAS G12C. Quality/risk of bias was assessed with RoB 2 and ROBINS-I.

Limitations

  • Stated: prevalence estimates came from studies using a wide variety of techniques, which may have contributed to outlier prevalence; few studies investigated tumor sidedness or compared response rates/duration; KRASm were not routinely assessed, limiting published outcome data; the review was not designed to definitively answer the research questions.
  • Stated/evident: heterogeneity in study populations, treatments, and prior lines of therapy made direct comparison of outcomes difficult; small sample sizes and inconsistent findings were noted; no publication reported time to response, depth of response, or treatment discontinuation in KRAS G12C patients.
  • Evident: some analyses relied on very few KRAS G12C patients (e.g., 6 patients for a stage II DFS analysis), and prevalence varied widely across geographies and studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/oncolo/oyad138

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. (A) Flow diagram depicting the screening and selection process for study selection in phase I (2009-2019) of the systematic literature search. (B) Flow diagram depicting the screening and selection process for study selection in phase II (2019-2021) of the systematic literature search. Abbreviations: CRC, colorectal cancer; KRASwt, wild-type Kirsten rat sarcoma virus gene; NSCLC, non-small cell lung cancer; SLR, systematic literature review.
Figure 1. (A) Flow diagram depicting the screening and selection process for study selection in phase I (2009-2019) of the systematic literature search. (B) Flow diagram depicting the screening and selection process for study selection in phase II (2019-2021) of the systematic literature search. Abbreviations: CRC, colorectal cancer; KRASwt, wild-type Kirsten rat sarcoma virus gene; NSCLC, non-small cell lung cancer; SLR, systematic literature review.CC BY-NC · PubMed Central
Figure 2. (A) Worldwide prevalence of KRAS G12C mutations in the entire cohort of included populations with colorectal cancer. (B) Worldwide prevalence of KRAS G12C mutations within the KRASm population in patients with colorectal cancer. *JAPAC, Japan & Asia-Pacific regions; **Intercontinental region: South America, Middle East. Abbreviation: KRASm, Kirsten rat sarcoma virus gene mutations.
Figure 2. (A) Worldwide prevalence of KRAS G12C mutations in the entire cohort of included populations with colorectal cancer. (B) Worldwide prevalence of KRAS G12C mutations within the KRASm population in patients with colorectal cancer. *JAPAC, Japan & Asia-Pacific regions; **Intercontinental region: South America, Middle East. Abbreviation: KRASm, Kirsten rat sarcoma virus gene mutations.CC BY-NC · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 50 Not checked · 63 Own results and interpretations

61 more claims

Create a free account to see all 113 claims and to verify the 61 references still open.

See all claims — free account
  • Probably not a substantial claim. 20
  • It may state two separate claims as one. 34
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Cited by

See all 54

Metadata

Authors
Strickler, J. H., Yoshino, T., Stevinson, K., Eichinger, C. S., Giannopoulou, C., Rehn, M., & Modest, D. P.
Affiliations
  • Duke Medical Center (US)
  • National Cancer Centre Japan (JP)
  • Amgen (United States) (US)
  • Value Demonstration Practice, Oxford Pharmagenesis , Oxford , UK
  • Amgen (Switzerland) (CH)
  • Charité – Universitätsmedizin Berlin (DE)
Corresponding author
Modest, Dominik Paul
Venue
The Oncologist
Published
2023-07-11
Volume
28
Issue
11
Pages
e981-e994
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W4383872273
Cited by
54
References
83
Citations by year
2026: 14 · 2025: 22 · 2024: 16 · 2023: 2
FWCI
1.58
Type
journal article
Language
en
Open access
Locations
  • The Oncologist (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Amgen Inc
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
KRAS G12C mutation, KRAS mutation, colorectal cancer, mutation prevalence, prognostic value, right-sided colon tumors, disease-free survival, relapse-free survival, objective response rate, co-occurring mutations
MeSH terms
Humans, Lung Neoplasms, Mutation, Neoplasm Recurrence, Local, Colorectal Neoplasms, Prevalence, Proto-Oncogene Proteins p21(ras)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.